Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-09
2011-08-09
Chung, Susannah (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S121000
Reexamination Certificate
active
07994190
ABSTRACT:
Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, and/or AP-1 and/or NF-κB activity including inflammatory and immune diseases, obesity and diabetes having the structure of formula (I):, its enantiomers, diastereomers, or a pharmaceutically-acceptable salt, or hydrate, thereof, wherein the group X is O or (Rx)(Ry); is heterocyclo or heteroaryl; E is —N—, —NR1—, —O—, —C(═O), —S—, —SO2—, or —CR2—; F is —N—, —NR1a, —O—, —C(═O), —S—, —SO2—, or —CR2a—; G is independently N, —NR1b—, —O—, —C(═O), —S—, —SO2— or —CR2b— provided that the heterocyclic ring formed does not contain a S—S or S—O bond and at least one of E, F and G is a hetero atom; and Ma, Rx, Ry, R1, R1a, R1b, R2, R2a, R2b, R4, R5a, R6, R7, X, Zaand Z are as defined herein. Also provided are pharmaceutical compositions and methods of treating inflammatory- or immune-associated diseases employing said compounds.
REFERENCES:
patent: 2004/0235888 (2004-11-01), Yamamori et al.
patent: 2004/0266751 (2004-12-01), King
patent: 2005/0234058 (2005-10-01), Mahaney et al.
patent: 2007/0037974 (2007-02-01), Brotherton-Pleiss et al.
patent: 0 644 182 (1995-03-01), None
patent: WO 92/19239 (1992-11-01), None
patent: WO 00/17201 (2000-03-01), None
patent: WO 03/024962 (2003-03-01), None
patent: WO 2004/080390 (2004-09-01), None
patent: WO 2004/108137 (2004-12-01), None
patent: WO 2005/037279 (2005-04-01), None
patent: WO 2005/037283 (2005-04-01), None
patent: WO 2006/071609 (2006-07-01), None
patent: WO 2006/132275 (2006-12-01), None
patent: WO 2008/057856 (2008-05-01), None
patent: WO 2008/057857 (2008-05-01), None
patent: WO 2008/057859 (2008-05-01), None
patent: WO 2008/057862 (2008-05-01), None
Baldwin, Jr., A.S., “The transcription factor NF-κB and human disease”, The Journal of Clinical Investigation, vol. 107, No. 1, pp. 3-6 (2001).
Burke, J.R., “Targeting IκB kinase for the treatment of inflammatory and other disorders”, Current Opinion in Drug Discovery & Development, vol. 6, No. 5, pp. 720-728 (2003).
Caldenhoven, E. et al., “Negative Cross-Talk between ReIA and the Glucocorticoid Receptor: A Possible Mechanism for the Antiinflammatory Action of Glucocorticoids”, Molecular Endocrinology, vol. 9, No. 4, pp. 401-412 (1995).
Chakravarti, D. et al., “Role of CBP/P300 in nuclear receptor signalling”, Nature, vol. 383, pp. 99-103 (1996).
Diamond, M.I. et al., “Transcription Factor Interactions: Selectors of Positive or Negative Regulation from a Single DNA Element”, Science, vol. 249, pp. 1266-1272 (1990).
Firestein, G.S. et al., “Signal Transduction and Transcription Factors in Rheumatic Disease”, Arthritis & Rheumatism, vol. 42, No. 4, pp. 609-621 (1999).
Jonat, C. et al., “Antitumor Promotion and Antiinflammation: Down-Modulation of AP-1 (Fos/Jun) Activity by Glucocorticoid Hormone”, Cell, vol. 62, pp. 1189-1204 (1990).
Kamei, Y. et al., “A CBP Integrator Complex Mediates Transcriptional Activation and AP-1 Inhibition by Nuclear Receptors”, Cell, vol. 85, pp. 403-414 (1996).
Manning, A.M., et al., “Targeting JNK for Therapeutic Benefit: from Junk to Gold?”, Nature, vol. 2, pp. 554-565 (2003).
Miesfeld, R. et al., “Characterization of a steroid hormone receptor gene and mRNA in wild-type and mutant cells”, Nature, vol. 312, pp. 779-781 (1984).
Peltz, G., “Transcription factors in immune-mediated disease”, Current Opinion in Biotechnology, vol. 8, pp. 467-473 (1997).
Reichardt, H.M. et al., “DNA Binding of the Glucocorticoid Receptor is Not Essential for Survival”, Cell, vol. 93, pp. 531-541 (1998).
Reichardt, H.M. et al., “Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor”, The EMBO Journal, vol. 20, No. 24, pp. 7168-7173 (2001).
Weinberger, C. et al., “Domain structure of human glucocorticoid receptor and its relationship to the v-erb-Aoncogene product”, Nature, vol. 318, pp. 670-672 (1985).
Weinberger, C. et al., “Identification of Human Glucocorticoid Receptor Complementary DNA Clones by Epitope Selection”, Science, vol. 228, pp. 740-742 (1985).
Yang-Yen, H.-F. et al., “Transcriptional Interference between c-Jun and the Glucocorticoid Receptor: Mutual Inhibition of DNA Binding Due to Direct Protein-Protein Interaction”, Cell, vol. 62, pp. 1205-1215 (1990).
Yin, L. et al., “New Calcineurin Inhibiting 3-Dimethylaminopropyl Substituted Diarylheterocycles by Sonogashira Reactions and Catalytic Hydrogenation”, J. Heterocyclic Chem., vol. 42, pp. 1369-1379 (2005).
Dhar T. G. Murali
Sheppeck James E.
Xiao Hai-Yun
Bristol--Myers Squibb Company
Chung Susannah
Duncan Laurelee A.
Rodney Burton
LandOfFree
Modulators of glucocorticoid receptor, AP-1, and/or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulators of glucocorticoid receptor, AP-1, and/or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulators of glucocorticoid receptor, AP-1, and/or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2630962